BRCA2 and neoplasm: We performed analyses on a large collection of data from ovarian cancer cases, including BRCA1 and BRCA2 (likely) pathogenic variant carriers and non-carriers, to assess histology and other tumour characteristics as predictors of germline BRCA1 and BRCA2 variant pathogenicity, with the aim of standardising the application of this evidence in clinical variant curation using the ACMG/AMP classification system, to inform the future interpretation of VUS in BRCA1 and BRCA2.